Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06612411
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-12
Brief Title:
BSubtilis Attenuate Symptoms in Diarrhea-predominant Irritable Bowel Syndrome by Increasing Hypoxanthine Biosynthesis
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Purine Starvation Driven by Host-microbiota Maladaptation Contributes to the Pathogenesis of Irritable Bowel Syndrome
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a prospective single-blind randomized parallel study to investigate whether B subtilis could improve clinical symptoms of IBS-D patients Patients are randomly assigned by envelope method A senior gastroenterologist is responsible for prescribing medication Researchers are blind to patients medication Participants with IBS are recruited and randomized to receive a 4-week administration of B subtilis-based probiotics Clinical symptoms and stool samples are collected before and after the trial
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None